. 2015 Jun 30;78(3):161–167. doi: 10.4046/trd.2015.78.3.161

Table 2. Comparisons of current trials which aimed to shorten duration of TB treatment.

graphic file with name trd-78-161-i002.jpg

^*Adjusted difference, experimental group-control group, percentage points (OFLOTUB, 95% CI; REMoxTB, 97.5% CI; RIFAQAUIN, 90% CI). TB: tuberculosis; ITT: intention-to-treat; Control: 2HREZ/4HR; G: gatifloxacin; H: isoniazid; R: rifampin; Z: pyrazinamide; NA: not applicable; INH: isoniazid; EMB: ethambutol; M: moxifloxacin; E: ethambutol; P: rifapentine; PM₂: twice weekly moxifloxacin and rifapentine; PM₁: once-weekly moxifloxacin and rifapentine; CI: confidence interval.